Together, these results demonstrate that mXJ104 enhances antifungal immunity in murine candidemia models by augmenting IFN-γ and IL-17 production, supporting further investigation of mXJ104’s protective efficacy in Candida infected models. This evidence concerns the gene IL17A and Candidemia.